氟维司群、哌柏西利和厄达替尼治疗ER阳性/PR阴性/HER2阴性转移性乳腺癌患者后出现3级肝毒性：一例报告
Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report.
作者信息
Schlotman Alyssa, Stater Adam, Schuler Kyle, Heideman Judd, Abramson Vandana
机构信息
Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
出版信息
Case Rep Oncol. 2020 Mar 24;13(1):304-308. doi: 10.1159/000506442. eCollection 2020 Jan-Apr.
Abstract
A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.
摘要
一名49岁的雌激素受体阳性/孕激素受体阴性/人表皮生长因子受体2阴性的转移性乳腺癌女性患者，在开始氟维司群、哌柏西利和厄达替尼的临床试验后出现了3级肝毒性。氟维司群被确定为最有可能导致这种肝毒性作用的药物。本病例报告详细描述了这种药物性肝损伤的发生时间和性质，为现有文献中尚未充分描述的领域提供了支持。
相似文献
1
Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report.氟维司群、哌柏西利和厄达替尼治疗ER阳性/PR阴性/HER2阴性转移性乳腺癌患者后出现3级肝毒性：一例报告
Case Rep Oncol. 2020 Mar 24;13(1):304-308. doi: 10.1159/000506442. eCollection 2020 Jan-Apr.
2
Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.哌柏西利联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期/转移性乳腺癌日本患者的疗效和安全性。
In Vivo. 2019 Nov-Dec;33(6):2037-2044. doi: 10.21873/invivo.11701.
3
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.曲妥珠单抗和帕妥珠单抗联合哌柏西利和氟维司群新辅助治疗人表皮生长因子受体 2 阳性、雌激素受体阳性乳腺癌（NA-PHER2）：一项探索性、开放标签、Ⅱ期研究。
Lancet Oncol. 2018 Feb;19(2):249-256. doi: 10.1016/S1470-2045(18)30001-9. Epub 2018 Jan 8.
4
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).帕博西尼联合氟维司群治疗激素受体阳性/人表皮生长因子受体2阴性晚期转移性乳腺癌女性患者：一项多中心、随机、安慰剂对照、III期研究（PALOMA-3）的详细安全性分析
Oncologist. 2016 Oct;21(10):1165-1175. doi: 10.1634/theoncologist.2016-0097. Epub 2016 Jul 1.
5
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.在真实世界环境中，美国接受帕博西尼联合芳香化酶抑制剂或氟维司群治疗 HR+/HER2-晚期/转移性乳腺癌患者的治疗模式和临床结局：IRIS 研究结果。
Breast. 2019 Feb;43:22-27. doi: 10.1016/j.breast.2018.10.009. Epub 2018 Oct 20.
6
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.哌柏西利联合氟维司群治疗晚期乳腺癌的总生存期
N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.
7
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.帕博西尼：一种用于激素受体阳性晚期乳腺癌的新型细胞周期蛋白依赖性激酶抑制剂。
Ann Pharmacother. 2015 Nov;49(11):1252-60. doi: 10.1177/1060028015602273. Epub 2015 Aug 31.
8
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.FDA 批准帕博西尼联合氟维司群用于治疗激素受体阳性、HER2 阴性转移性乳腺癌。
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972. doi: 10.1158/1078-0432.CCR-16-0493. Epub 2016 Jul 12.
9
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.绝经后激素受体阳性、人表皮生长因子受体-2 阴性转移性乳腺癌患者在非甾体芳香化酶抑制剂治疗进展后的基于内分泌治疗的无进展生存期：一项网络荟萃分析。
Curr Med Res Opin. 2018 Sep;34(9):1645-1652. doi: 10.1080/03007995.2018.1479246. Epub 2018 Jun 12.
10
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.帕博西尼联合正在进行的内分泌治疗用于激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌：病例报告系列
Mol Clin Oncol. 2020 May;12(5):456-460. doi: 10.3892/mco.2020.2016. Epub 2020 Mar 11.
引用本文的文献
1
Non-systemic Approaches for Ductal Carcinoma In Situ: Exploring the Potential of Ultra-flexible Combisomes as a Novel Drug Delivery Strategy-a Review.非系统性局部原位导管癌治疗方法：探索超灵活梳状囊泡作为新型药物输送策略的潜力——综述。
AAPS PharmSciTech. 2023 May 12;24(5):119. doi: 10.1208/s12249-023-02574-z.
2
Palbociclib-induced severe hepatitis: A case study and literature review.帕博西尼引起的严重肝炎：病例研究与文献综述
Can Liver J. 2021 Nov 11;4(4):433-437. doi: 10.3138/canlivj-2021-0015. eCollection 2021 Fall.
3
Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.药物性肝损伤：近期文献中的要点和争议。
Drug Saf. 2021 Nov;44(11):1125-1149. doi: 10.1007/s40264-021-01109-4. Epub 2021 Sep 17.
4
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.CDK4/6 抑制剂在乳腺癌治疗中的作用：与药物、基因和病理生理状况的潜在相互作用。
Int J Mol Sci. 2020 Sep 1;21(17):6350. doi: 10.3390/ijms21176350.
本文引用的文献
1
A Rare Case of Fulvestrant-Associated Jaundice and Hepatotoxicity.一例氟维司群相关黄疸和肝毒性的罕见病例。
Am J Ther. 2019 Jan/Feb;26(1):e122-e123. doi: 10.1097/MJT.0000000000000532.
2
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.帕博西尼联合内分泌治疗激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌的长期汇总安全性分析。
J Natl Cancer Inst. 2019 Apr 1;111(4):419-430. doi: 10.1093/jnci/djy109.
3
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.在晚期或难治性实体瘤患者中，泛成纤维细胞生长因子受体（FGFR）酪氨酸激酶抑制剂erdafitinib 的安全性、药代动力学和药效学。
Invest New Drugs. 2018 Jun;36(3):424-434. doi: 10.1007/s10637-017-0514-4. Epub 2017 Sep 30.
4
Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.哌柏西利治疗后转移性乳腺癌患者的假性肝硬化和肝衰竭
Hepatology. 2017 May;65(5):1762-1764. doi: 10.1002/hep.28720. Epub 2016 Aug 9.
5
Hepatotoxicity Secondary to Chemotherapy.化疗相关肝毒性。
J Clin Transl Hepatol. 2014 Jun;2(2):95-102. doi: 10.14218/JCTH.2014.00011. Epub 2014 Jun 15.
6
Drug-induced liver disease.药物性肝病
Clin Liver Dis. 2000 Feb;4(1):73-96, vi. doi: 10.1016/s1089-3261(05)70097-0.
Zotero 插件